FDAnews
www.fdanews.com/articles/70062-cytogen-provides-quadramet-development-commercialization-update

Cytogen Provides Quadramet Development, Commercialization Update

March 21, 2005

Cytogen has provided an update regarding clinical development and commercialization activities for Quadramet.

Quadramet (samarium Sm-153 lexidronam injection), Cytogen's flagship product, is a fast-acting, long-lasting nonopioid therapeutic alternative for the relief of pain due to metastatic bone disease arising from prostate, breast, multiple myeloma and other types of cancer.

Cytogen announced that researchers at Memorial Sloan-Kettering Cancer Center will investigate the use of Quadramet in combination with docetaxel for the treatment of metastatic bone disease arising from prostate cancer. This new clinical study will evaluate the safety profile and preliminary incidence and duration of clinical benefits of docetaxel in combination with Quadramet. The study will be carried out under Cytogen's investigational new drug application.